EQS Group-Ad-hoc: Medacta Group SA / Key word(s): Change in Forecast
Medacta Group SA announces a revision of the full year guidance
05-Dec-2019 / 19:48 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 KR
The issuer is solely responsible for the content of this announcement.
*Press Release
2019 GUIDANCE REVISION*
_CASTEL SAN PIETRO_, _5 December 2019_ - Medacta Group SA announces a
revision of the full year guidance.
The company continues to expand, achieving strong revenue growth well above
the market growth rate while maintaining a high profitability level.
Following an unexpected weak demand in the US and in some minor markets
covered by distributors, the overall growth rate in November was below
expectations, 8% compared to 17% of the same period of last year. This
performance changed the scenario of the year-end forecasted results.
Accordingly, the year-end 2019 guidance is as follows:
- *Revenue*: reported growth in the range of 12-14%, equal to 10-12% on a
constant currency basis (previously equal to 13-17%)
- *Adjusted EBITDA*: approximately 30% +/-1% (previously 32% +/-1%)
- *Change in Net Working Capital*: 5-7% of total revenue (maintained)
- *CapEx*: 12-15% of total revenue (previously 10-12%)
We expect that this revision on full year performance does not affect the
mid-term performance.
Medacta is planning to report preliminary unaudited top-line figures on 21
January 2020 and full-year 2019 results on 6 April 2020.
*Contact*
Medacta Group SA
Corrado Farsetta, CFO
Phone: +41 91 696 60 60
investor.relations@medacta.ch
*About Medacta:*
Medacta is an international company specializing in the design and
production of innovative orthopaedic products and the development of
accompanying surgical techniques for joint replacement, spine surgery, and
sports medicine. Established in 1999 in Switzerland, Medacta's products and
surgical techniques are characterized by innovation. Medacta is a pioneer in
developing new offerings on the basis of minimally invasive surgical
techniques, in particular its Anterior Minimally Invasive Surgery ("AMIS")
technique for hip replacements. Medacta has leveraged its orthopaedic
expertise and comprehensive understanding of the human body to develop the
sophisticated "_MySolutions_" technology, which offers surgeons highly
personalized pre-operative planning and implant placement methodologies by
creating advanced personalized kinematic models and 3D planning tools for
use in hip, knee, shoulder and spine procedures.
End of ad hoc announcement
Language: English
Company: Medacta Group SA
Strada Regina
6874 Castel San Pietro
Switzerland
Phone: +41 91 696 6060
E-mail: info@medacta.ch, investor.relations@medacta.ch
Internet: www.medacta.com
ISIN: CH0468525222
Listed: SIX Swiss Exchange
EQS News ID: 929805
End of Announcement EQS Group News Service
929805 05-Dec-2019 CET/CEST
(END) Dow Jones Newswires
December 05, 2019 13:48 ET (18:48 GMT)
© 2019 Dow Jones News
